Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 1;50(6):386-394.
doi: 10.1097/OLQ.0000000000001782. Epub 2023 Feb 8.

Health Care Provider Decisions to Initiate Oral HIV Preexposure Prophylaxis in New York City Public Sexual Health Clinics

Affiliations

Health Care Provider Decisions to Initiate Oral HIV Preexposure Prophylaxis in New York City Public Sexual Health Clinics

Susie Hoffman et al. Sex Transm Dis. .

Abstract

Background: Oral HIV preexposure prophylaxis (PrEP) is safe and effective but underutilized. Health care providers' beliefs about PrEP and attitudes toward people who could benefit may affect PrEP access.

Methods: This mixed-methods study (2016-2018) was conducted in 8 New York City public sexual health clinics that implemented a PrEP program. Data included 32 in-depth qualitative interviews with clinicians, quantitatively coded to reflect their PrEP beliefs; a provider questionnaire; and 6 months of medical record visit data for these providers. Among patients with a PrEP indication, we examined the odds of a patient being initiated on PrEP associated with providers' PrEP beliefs and demographic characteristics, and patient characteristics.

Results: Providers reported strong support for offering PrEP to eligible patients. The majority denied concerns about possible development of drug-resistant viral strains, giving PrEP to people who might not benefit, and PrEP toxicity. Nevertheless, about one-third agreed with each of these concerns, and 55% thought PrEP use might limit condom use. Of 2176 patients with a PrEP indication, 20% were initiated. Providers with more restrictive PrEP beliefs did not have lower odds of initiating patients on PrEP. Women as well as Black and Latinx patients were less likely to be initiated on PrEP.

Conclusions: Contrary to our hypotheses, providers' negative PrEP beliefs did not seem to reduce initiation of PrEP for eligible patients. This may be attributable to clear clinical protocols, strong staff support, and training on implementing PrEP in this setting. Racial and gender disparities in PrEP uptake urgently require attention.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest and Sources of Funding: None declared.

Figures

Figure 1.
Figure 1.. Inclusion & exclusion criteria among patient-visits by 32 providers, Sexual Health Clinics, New York City, 2017–2018
1 Included visits occurring in the 182 days prior to interview date. Excludes visits if a) Patient is HIV-positive, b) Visit occurred prior to PrEP initiation roll-out, c) Patient initiated PrEP at SHC prior to DOV, d) Patient medically evaluated for PrEP at SHC prior to current visit 2 Ineligible for PrEP initiation if: a) patient aged <18 years, b) Visit occurred on a Saturday, c) Non-NYC resident, d) patient received PEP medication at current visit 3 Indication for PrEP if: a) patient self-reported at triage or navigation on DOV one or more of the following in the last 12 months: sex partner or needle sharing with PLWH, PEP use, syphilis diagnosis, and/or rectal gonorrhea or chlamydia, b) patient was clinically diagnosed with syphilis on DOV or at a SHC visit in the last 12 months, c) patient had a positive rectal gonorrhea and/or chlamydia test at a SHC visit in the last 12 months, d) patient is a woman with a positive gonorrhea test at a SHC visit in the last 12 months from any anatomic site, e) patient self- reported interest in PrEP at triage or navigation on DOV

Similar articles

Cited by

References

    1. U.S. Department of Health & Human Services, U.S. Food and Drug Administration. Truvada for PrEP fact sheet: Ensuring safe and proper use. 2012. Available at: https://www.fda.gov/media/83586/download. Accessed May 13, 2022.
    1. Centers for Disease Control and Prevention, US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: A clinical practice guideline. 2021. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Accessed March 7, 2022.
    1. Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through June 2021; and preexposure prophylaxis (PrEP) data reported through March 2021. HIV Surveillance Data Tables 2021;2(No. 4). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published October 2021. Accessed August 30 2022
    1. AIDSVu. PrEP use across the U.S. at the county-level. 2020. Available at: https://aidsvu.org/aidsvu-releases-landmark-county-level-data-and-intera.... Accessed November 26, 2021.
    1. Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol 2018;28(12):841–849. - PMC - PubMed

Publication types

Substances